Total Payments
$103,504
2024 Payments
$23,326
Companies
7
Transactions
100
Medicare Patients
567
Medicare Billing
$49,452
Payment Breakdown by Category
Consulting$56,620 (54.7%)
Research$30,170 (29.1%)
Other$8,050 (7.8%)
Travel$6,369 (6.2%)
Food & Beverage$2,257 (2.2%)
Education$38.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $56,620 | 16 | 54.7% |
| Unspecified | $30,170 | 26 | 29.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,050 | 2 | 7.8% |
| Travel and Lodging | $6,369 | 22 | 6.2% |
| Food and Beverage | $2,257 | 33 | 2.2% |
| Education | $38.00 | 1 | 0.0% |
Payments by Type
General
$73,334
74 transactions
Research
$30,170
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie, Inc. | $52,303 | 37 | $0 (2018) |
| F. Hoffmann-La Roche AG | $27,767 | 29 | $0 (2024) |
| Merck Sharp & Dohme LLC | $11,350 | 9 | $0 (2024) |
| Gilead Sciences, Inc. | $10,005 | 19 | $0 (2020) |
| Roche Products Limited | $1,815 | 1 | $0 (2022) |
| EyePoint Pharmaceuticals US, Inc. | $226.09 | 4 | $0 (2023) |
| Hoffmann-La Roche Limited | $38.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,326 | 22 | F. Hoffmann-La Roche AG ($11,977) |
| 2023 | $12,579 | 15 | F. Hoffmann-La Roche AG ($12,463) |
| 2022 | $5,143 | 3 | F. Hoffmann-La Roche AG ($3,328) |
| 2020 | $120.97 | 1 | Gilead Sciences, Inc. ($120.97) |
| 2019 | $248.59 | 5 | Gilead Sciences, Inc. ($138.85) |
| 2018 | $15,329 | 23 | AbbVie, Inc. ($14,718) |
| 2017 | $46,758 | 31 | AbbVie, Inc. ($37,585) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $9,165.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $60.02 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.01 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $1,283.38 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $345.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $150.80 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $75.40 | General |
| Category: IMMUNOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,181.71 | Research |
| Study: IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Study Design of the Phase 3 MEERKAT and SANDCAT trials | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $919.11 | Research |
| Study: IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $783.00 | Research |
| Study: Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $600.00 | Research |
| Study: IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 1 DOVETAIL, and Phase 3 MEERKAT and SANDCAT Trials | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $481.43 | Research |
| Study: IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials | ||||||
| 08/23/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,485.00 | Research |
| Study: IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $320.00 | Research |
| Study: Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $240.71 | Research |
| Study: Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study | ||||||
| 04/01/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,109.17 | Research |
| Study: IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $481.43 | Research |
| Study: IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials | ||||||
| 03/22/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $799.28 | Research |
| Study: Intravitreal anti-IL-6 mAb for UME: preliminary results from a phase 1 study | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $585.63 | Research |
| Study: A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study | ||||||
| 12/31/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $551.18 | Research |
| Study: A novel intravitreal anti-IL-6 monoclonal antibody for UME: preliminary results from the phase 1 DOVETAIL study | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M11-327 | AbbVie, Inc. | $16,657 | 7 |
| IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials | F. Hoffmann-La Roche AG | $5,476 | 5 |
| A novel intravitreal anti-IL-6 monoclonal antibody for UME: preliminary results from the phase 1 DOVETAIL study | F. Hoffmann-La Roche AG | $2,615 | 4 |
| A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study | F. Hoffmann-La Roche AG | $1,437 | 3 |
| Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study | F. Hoffmann-La Roche AG | $1,344 | 3 |
| IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Study Design of the Phase 3 MEERKAT and SANDCAT trials | F. Hoffmann-La Roche AG | $1,182 | 1 |
| Intravitreal anti-IL-6 mAb for UME: preliminary results from a phase 1 study | F. Hoffmann-La Roche AG | $799.28 | 1 |
| IL-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 1 DOVETAIL, and Phase 3 MEERKAT and SANDCAT Trials | F. Hoffmann-La Roche AG | $600.00 | 1 |
| A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non infectious Uveitis | Gilead Sciences, Inc. | $61.05 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 147 | 257 | $48,008 | $12,602 |
| 2022 | 5 | 206 | 332 | $56,308 | $16,074 |
| 2021 | 3 | 115 | 262 | $36,650 | $12,160 |
| 2020 | 3 | 99 | 221 | $15,373 | $8,616 |
Total Patients
567
Total Services
1,072
Medicare Billing
$49,452
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 65 | 130 | $36,459 | $9,289 | 25.5% |
| 92134 | Imaging of retina | Facility | 2023 | 62 | 99 | $6,237 | $1,913 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 20 | 28 | $5,312 | $1,400 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 65 | 117 | $30,722 | $8,707 | 28.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 44 | 70 | $12,358 | $3,364 | 27.2% |
| 92134 | Imaging of retina | Facility | 2022 | 70 | 117 | $7,303 | $2,212 | 30.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $4,268 | $1,252 | 29.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2022 | 15 | 16 | $1,657 | $539.20 | 32.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 38 | 94 | $21,350 | $7,041 | 33.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 52 | $8,108 | $2,794 | 34.5% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 55 | 116 | $7,192 | $2,325 | 32.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Facility | 2020 | 35 | 86 | $7,339 | $5,086 | 69.3% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Facility | 2020 | 26 | 50 | $2,726 | $1,878 | 68.9% |
| 92134 | Diagnostic imaging of retina | Facility | 2020 | 38 | 85 | $5,308 | $1,651 | 31.1% |
About Dr. Eric Suhler, MD
Dr. Eric Suhler, MD is a Ophthalmology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275585143.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Suhler, MD has received a total of $103,504 in payments from pharmaceutical and medical device companies, with $23,326 received in 2024. These payments were reported across 100 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($56,620).
As a Medicare-enrolled provider, Suhler has provided services to 567 Medicare beneficiaries, totaling 1,072 services with total Medicare billing of $49,452. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Uveitis and Ocular Inflammatory Disease
- Location Portland, OR
- Active Since 05/17/2006
- Last Updated 11/09/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1275585143
Products in Payments
- Humira (Biological) $52,303
- YUTIQ (Drug) $226.09
- Lucentis (Biological) $38.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Portland
James Rosenbaum, M.d, M.D
Ophthalmology — Payments: $293,531
Ophthalmology $293,531
Dr. Mark Pennesi, Md Phd, MD PHD
Ophthalmology — Payments: $185,243
Ophthalmology $185,243
Peter Francis, Md, MD
Ophthalmology — Payments: $156,902
Ophthalmology $156,902
Roger Dailey, Md, MD
Ophthalmology — Payments: $135,004
Ophthalmology $135,004
Dr. Brian Chan-Kai, M.d, M.D
Ophthalmology — Payments: $123,899
Ophthalmology $123,899
Dr. Mark Terry, Md, MD
Ophthalmology — Payments: $112,572
Ophthalmology $112,572